The tendency of both labeled and unlabeled beta-amyloid to bind in solution to C1q, the recognition species in the complement cascade, was examined using both hydrodynamic and spectroscopic methods. Potential binding interactions were evaluated using a purified synthetic beta-amyloid 1-40 sequence, alone, and selectively labeled at the amino terminus with spectroscopic probes. The probes permitted both absorbance and fluorescence analyses of beta-amyloid binding interactions. Under conditions used for the analyses beta-amyloid exists exclusively as a monomer in solution, and C1q retains an intact quaternary structure and is capable of binding to IgM. When mixed together the monomeric beta-amyloid does not bind to, or interact with, the complement C1q at concentrations below approximately 100 microM. The data suggest that if beta-amyloid toxicity is associated with complement activation in Alzheimer's disease then monomeric beta-amyloid is likely not responsible for activation through the classical complement pathway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/exnr.1994.1121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipid-induced condensate formation from the Alzheimer's Aβ peptide triggers amyloid aggregation.
Proc Natl Acad Sci U S A
January 2025
Yusuf Hamied Department of Chemistry, Centre for Misfolding Diseases, University of Cambridge, Cambridge CB2 1EW, United Kingdom.
The onset and development of Alzheimer's disease is linked to the accumulation of pathological aggregates formed from the normally monomeric amyloid-β peptide within the central nervous system. These Aβ aggregates are increasingly successfully targeted with clinical therapies at later stages of the disease, but the fundamental molecular steps in early stage disease that trigger the initial nucleation event leading to the conversion of monomeric Aβ peptide into pathological aggregates remain unknown. Here, we show that the Aβ peptide can form biomolecular condensates on lipid bilayers both in molecular assays and in living cells.
View Article and Find Full Text PDFSurvey of the Aβ-peptide structural diversity: molecular dynamics approaches.
Biophys Rev
December 2024
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov str. 32, 119991 Moscow, Russia.
Unlabelled: The review deals with the application of Molecular Dynamics (MD) to the structure modeling of beta-amyloids (Aβ), currently classified as intrinsically disordered proteins (IDPs). In this review, we strive to relate the main advances in this area but specifically focus on the approaches and methodology. All relevant papers on the Aβ modeling are cited in the Tables in Supplementary Data, including a concise description of the applied approaches, sorted according to the types of the studied systems: modeling of the monomeric Aβ and Aβ aggregates.
View Article and Find Full Text PDFAβ40 Fibril Assembly on Human Cerebral Smooth Muscle Cells Impairs Cell Viability.
Biochemistry
January 2025
George and Anne Ryan Institute for Neuroscience, Department of Biomedical and Pharmacological Sciences, University of Rhode Island, Kingston, Rhode Island 02881, United States.
Cerebral vascular deposition of the amyloid-β (Aβ) peptide, a condition known as cerebral amyloid angiopathy (CAA), is associated with intracerebral hemorrhaging and contributes to disease progression in Alzheimer's disease (AD) and vascular cognitive impairment and dementia (VCID). Familial mutations at positions 22 and 23 within the Aβ peptide lead to early onset and severe CAA pathology. Here, we evaluate the effects of fibrillar Aβ peptides on the viability of primary-cultured human cerebral smooth muscle (HCSM) cells, which are the major site of amyloid deposition in cerebral blood vessel walls.
View Article and Find Full Text PDFNeprilysin-Mediated Amyloid Beta Clearance and Its Therapeutic Implications in Neurodegenerative Disorders.
ACS Pharmacol Transl Sci
December 2024
Centre for Advanced Research (CFAR), Faculty of Medicine, King George's Medical University (KGMU), Lucknow 226003, India.
Neprilysin (NEP) is a neutral endopeptidase, important for the degradation of amyloid beta (Aβ) peptides and other neuropeptides, including enkephalins, substance P, and bradykinin, in the brain, that influences various physiological processes such as blood pressure homeostasis, pain perception, and neuroinflammation. NEP breaks down Aβ peptides into smaller fragments, preventing the development of detrimental aggregates such as Aβ plaques. NEP clears Aβ plaques predominantly by enzymatic breakdown in the extracellular space.
View Article and Find Full Text PDFCovalent organic framework derived single-atom copper nanozymes for the detection of amyloid-β peptide and study of amyloidogenesis.
Anal Bioanal Chem
December 2024
College of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, Shijiazhuang, 050017, China.
Article Synopsis
- The study introduces a new colorimetric assay using single-atom Cu anchored N-doped carbon nanospheres (Cu-NCNSs) for the sensitive detection of amyloid-β (Aβ) monomers, which is key for early Alzheimer's diagnosis.
- The Cu-NCNSs show high peroxidase-like activity and a strong affinity for Aβ, allowing for a detection limit of 1.182 nM, outperforming traditional methods in efficiency and accuracy.
- The system also enables monitoring of Aβ aggregation dynamics and shows greater sensitivity to toxic Aβ oligomers compared to commonly used amyloid dyes, highlighting its potential for early detection and treatment of Alzheimer’s disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!